We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers (BMY) Reports Phase II Data on Psoriasis Drug
Read MoreHide Full Article
Bristol-Myers Squibb Company (BMY - Free Report) announced results from a phase II study on BMS-986165 in patients with moderate-to-severe plaque psoriasis. BMS-986165 is a novel, oral, selective TYK2 inhibitor with a unique mechanism of action, distinct from other kinase inhibitors.
In the phase II study, the patients received BMS-986165 in doses of 3 mg every other day (QOD), 3 mg every day (QD), 3 mg twice daily (BID), 6 mg BID , 12 mg QD, or placebo. The primary endpoint was Psoriasis Area and Severity Index (PASI) 75 at Week 12. Key secondary endpoints included PASI 90 and PASI 100 as well as Dermatology Life Quality Index (DLQI), a quality of life measure.
The study showed that efficacy endpoints including greater than or equal to 75% and 90% reduction in PASI 75, PASI 90 were achieved following 12 weeks of treatment with ≥3 mg daily of BMS-986165, with a favorable risk-benefit profile. Efficacy was seen regardless of a patient’s prior exposure to biologic therapy.
These data were published in the New England Journal of Medicine and presented at the 27th European Academy of Dermatology and Venerology (EADV) Congress.
Shares of the company have decreased 1.2% against the industry’s growth of 5.0% year to date.
Currently there are limited numbers of oral therapies available for the treatment of moderate-to-severe psoriasis and the data suggest that BMS-986165 may be a promising oral option to help patients control their psoriasis in future.
The company is also enrolling patients in a phase III POETYK program (Program to evaluate the efficacy and safety of BMS-986165, a selective TYK2 inhibitor). Phase II studies for patients with systemic lupus erythematosus or Crohn's disease are also ongoing.
We remind investors that Bausch Health Companies Inc.’s (BHC - Free Report) plaque psoriasis candidate, Duobrii received a Complete Response Letter (CRL) from the FDA for its new drug application (NDA) in June 2018. The CRL was issued due to questions related to pharmacokinetic data. However, the company resubmitted the NDA, which was accepted by the FDA as a Class 2 resubmission with a PDUFA action date of Feb 15, 2019.
Lilly’s earnings per share estimates have increased from $5.16 to $5.47 for 2018 and from $5.53 to $5.73 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 10.15%. The stock has rallied 23.2% in the past three months.
Roche’s earnings per share estimates have increased from $2.10 to $2.24 for 2018 and from $2.15 to $2.29 for 2019 over the past 60 days. The stock has rallied 15% in the past three months.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Bristol-Myers (BMY) Reports Phase II Data on Psoriasis Drug
Bristol-Myers Squibb Company (BMY - Free Report) announced results from a phase II study on BMS-986165 in patients with moderate-to-severe plaque psoriasis. BMS-986165 is a novel, oral, selective TYK2 inhibitor with a unique mechanism of action, distinct from other kinase inhibitors.
In the phase II study, the patients received BMS-986165 in doses of 3 mg every other day (QOD), 3 mg every day (QD), 3 mg twice daily (BID), 6 mg BID , 12 mg QD, or placebo. The primary endpoint was Psoriasis Area and Severity Index (PASI) 75 at Week 12. Key secondary endpoints included PASI 90 and PASI 100 as well as Dermatology Life Quality Index (DLQI), a quality of life measure.
The study showed that efficacy endpoints including greater than or equal to 75% and 90% reduction in PASI 75, PASI 90 were achieved following 12 weeks of treatment with ≥3 mg daily of BMS-986165, with a favorable risk-benefit profile. Efficacy was seen regardless of a patient’s prior exposure to biologic therapy.
These data were published in the New England Journal of Medicine and presented at the 27th European Academy of Dermatology and Venerology (EADV) Congress.
Shares of the company have decreased 1.2% against the industry’s growth of 5.0% year to date.
Currently there are limited numbers of oral therapies available for the treatment of moderate-to-severe psoriasis and the data suggest that BMS-986165 may be a promising oral option to help patients control their psoriasis in future.
The company is also enrolling patients in a phase III POETYK program (Program to evaluate the efficacy and safety of BMS-986165, a selective TYK2 inhibitor). Phase II studies for patients with systemic lupus erythematosus or Crohn's disease are also ongoing.
We remind investors that Bausch Health Companies Inc.’s (BHC - Free Report) plaque psoriasis candidate, Duobrii received a Complete Response Letter (CRL) from the FDA for its new drug application (NDA) in June 2018. The CRL was issued due to questions related to pharmacokinetic data. However, the company resubmitted the NDA, which was accepted by the FDA as a Class 2 resubmission with a PDUFA action date of Feb 15, 2019.
Bristol-Myers Squibb Company Price
Bristol-Myers Squibb Company Price | Bristol-Myers Squibb Company Quote
Zacks Rank & Other Stocks to Consider
Bristol-Myers is a Zacks Rank #1 (Strong Buy) stock.
Other top-ranked stocks in the same space are Roche Holding AG (RHHBY - Free Report) , and Eli Lilly and Company (LLY - Free Report) . While Roche carries a Zacks Rank #1, Lilly sports a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Lilly’s earnings per share estimates have increased from $5.16 to $5.47 for 2018 and from $5.53 to $5.73 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 10.15%. The stock has rallied 23.2% in the past three months.
Roche’s earnings per share estimates have increased from $2.10 to $2.24 for 2018 and from $2.15 to $2.29 for 2019 over the past 60 days. The stock has rallied 15% in the past three months.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>